US Edition
Everest Medicines Announces Placement of Shares to Raise Approximately hk$1.5725 Billion
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
Shanghai, July 25, 2025 - (Asia Pacific Business News via SeaPRwire.com) - Everest Medicines Limited (HKEX1952.HK), a biopharmaceutical company focused on innovative drug research and development, clinical development, manufacturing and commercialization, today announced the placement of 22,561,000 shares on a first-for-new basis, raising approximately HK$1.5725 billion. The number of shares issued accounts for approximately 6.87% of the existin…
Shanghai, July 25, 2025 - (Asia Pacific Business News via SeaPRwire.com) - Everest Medicines Limited (HKEX1952.HK), a biopharmaceutical company focused on innovative drug research and development, clinical development, manufacturing and commercialization, today announced the placement of 22,561,000 shares on a first-for-new basis, raising approximately HK$1.5725 billion. The number of shares issued accounts for approximately 6.87% of the existin…
SHANGHAI, July 25, 2025 /PRNewswire/ — Everest Medicines Limited (HKEX1952.HK), a biopharmaceutical company focused on innovative drug research and development, clinical development, manufacturing and commercialization, today announced the placement of 22,561,000 shares on a first-for-new basis, raising approximately HK$1.5725 billion. The number of shares issued accounts for approximately 6.87% of the existing share capital and approximately 6.…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
